Search Results
Your search for ,wAS matches 27454 pages
Showing 17351 - 17400ASCO 2017: Healthy Lifestyle After Colon Cancer Diagnosis Helps Extend Survival
A study of 992 patients with stage III colon cancer found that those who reported a healthy lifestyle during and following adjuvant treatment had a 42% lower chance of death and a trend for lower chance of cancer recurrence than those who had less healthy lifestyles. The study will be presented by...
ASCO 2017: Increase in Early-Stage Cancer Diagnoses After Implementation of the Affordable Care Act
An analysis of nearly 273,000 patients showed that between 2013 and 2014 there was a 1% increase in the percentage of breast, lung, and colorectal cancers diagnosed at the earliest, most treatable stage. Considering the thousands of people diagnosed with these cancers annually, a 1% increase in...
ASCO 2017: Adjuvant Capecitabine May Extend Survival in Biliary Tract Cancer
A phase III randomized clinical trial in 447 patients with biliary tract cancers showed that treating the disease with capecitabine after surgery extends survival by a median of 15 months compared to surgery alone. The finding could provide the basis for a new standard of care in the disease. This ...
Surveillance and Colorectal Cancer Risk in Patients With Intermediate-Risk Adenomas
A UK retrospective study showed that colonoscopic surveillance was associated with a reduced risk of colorectal cancer among patients with removal of intermediate-risk adenomas. The study was reported in The Lancet Oncology by Atkin et al. Study Details The study involved routine lower...
Long-Term Follow-up of Intergroup Exemestane Study
A final efficacy analysis of the Intergroup Exemestane Study, reported in the Journal of Clinical Oncology by Morden et al, shows continued benefit of switching to adjuvant exemestane after 2 to 3 years of tamoxifen in patients with early breast cancer. Study Details In the trial, patients who...
First-in-Class T-Cell Stimulator Varlilumab in Advanced Solid Tumors
A phase I study reported by Burris et al in the Journal of Clinical Oncology has shown that the first-in-class agonist anti-CD27 antibody varlilumab is well tolerated and active in patients with advanced solid tumors. CD27 is a co-stimulatory molecule on T cells that induces intracellular signaling ...
Delaying Colonoscopy for 9 Months or More After Positive Fecal Screening Test May Increase Risk of Colorectal Cancer
The risk of colorectal cancer increased significantly when colonoscopy was delayed by more than 9 months following a positive fecal screening test, according to a large Kaiser Permanente study published by Rutter et al in the Journal of the American Medical Association. “With this study, we...
Hypofractionated Postmastectomy Radiation in Breast Cancer
In a phase II trial, Khan et al found that hypofractionated postmastectomy radiotherapy, completed in 15 treatment days, was safe and effective in women with stage II to IIIa breast cancer. The study was reported in the Journal of Clinical Oncology. Study Details In the study, 67 women from 2...
Changes in HER2 Breast Cancer Testing According to 2007 and 2013 ASCO/CAP Guidelines
Hanna et al have reported that the 2013 update to the 2007 ASCO/College of American Pathologists (CAP) recommendations for HER2 testing in breast cancer did not result in changes in the overall HER2-positivity rate but was associated with a higher rate of equivocal results. Their findings were...
Reduced-Intensity vs Standard Conditioning Followed by ASCT in Myelodysplastic Syndrome
In the phase III RICMAC trial, use of a dose-reduced vs a standard myeloablative conditioning regimen prior to allogeneic stem cell transplantation (ASCT) did not appear to reduce 2-year relapse-free or overall survival in patients with myelodysplastic syndrome. These findings were reported by...
ASCO Remembers Robert L. Comis, MD, FASCO
ASCO and the oncology community are deeply saddened by the loss of Robert L. Comis, MD, FASCO, who passed away on May 10, 2017, at the age of 71. Dr. Comis was a powerful voice in support of clinical trials, cooperative group research, and patient advocacy throughout his career. “Bob helped...
Cost of Hospitalization for Cancer-Related Neutropenia or Fever
In a study of 2012 data, Tai et al, of the Centers for Disease Control and Prevention, estimated that average costs per hospital stay for cancer-related neutropenia or fever were approximately $25,000, with a total cost of more than $2.7 billion. Their study was published in the Journal of Oncology ...
Adding Pertuzumab to Trastuzumab/Capecitabine in Pretreated HER2-Positive Metastatic Breast Cancer
The phase III PHEREXA trial has shown no significant improvement in progression-free survival with the addition of pertuzumab (Perjeta) to trastuzumab (Herceptin)/capecitabine in patients with HER2-positive metastatic breast cancer with disease progression during or after trastuzumab-based...
FDA Approves Ribociclib/Letrozole Co‑Pack for Postmenopausal Patients With Advanced or Metastatic Breast Cancer
On May 8, the U.S. Food and Drug Administration (FDA) approved the copackaging of ribociclib (Kisqali) and letrozole (Femara) tablets for the treatment of hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in postmenopausal ...
FDA Approves Pembrolizumab as First-Line Combination Therapy With Pemetrexed and Carboplatin for Metastatic Nonsquamous NSCLC
On May 10, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda), an anti–programmed cell death protein 1 (PD-1) therapy, in combination with pemetrexed (Alimta) and carboplatin for the first-line treatment of metastatic nonsquamous non–small cell lung cancer...
ONS 2017: Hospital-Wide Initiative to Standardize the Administration of Vinca Alkaloids Using a Mini-Bag, Side-Arm Technique
Many patients with cancer who receive vinca alkaloids such as vincristine have a treatment regimen including other chemotherapy drugs that are administered intrathecally. If vincristine is mistakenly administered into the spinal fluid, it is uniformly fatal, causing ascending paralysis, neurologic...
ESTRO 2017: Study Suggests Role for Radiotherapy in Extending Survival in Patients With Early-Stage Pancreatic Cancer
Radiotherapy at a high enough dose may increase survival in early-stage pancreatic cancer, according to research presented at the European Society for Radiotherapy & Oncology (ESTRO) 36 Conference (Abstract OC-0426). Previous research has suggested that radiotherapy may be of little help to...
ESTRO 2017: HDR Brachytherapy in Prostate Cancer Does Not Cause Higher Toxicity, Results in High Patient Satisfaction
Treating prostate cancer with a single, high dose of radiation delivered precisely to the site of the tumor results in good quality of life and fewer trips to the hospital, with adverse side effects that are no worse than if the radiation treatment had been given in several lower doses. These...
Update to Guideline for Management of Fever and Neutropenia in Children With Cancer and HSCT Recipients
An update to the 2012 International Pediatric Fever and Neutropenia Guideline Panel recommendations for management of fever and neutropenia in children with cancer and hematopoietic stem cell transplantation (HSCT) recipients was reported by Lehrnbecher et al in the Journal of Clinical Oncology....
USPSTF Recommendation on Screening for Thyroid Cancer
As reported in JAMA, the U.S. Preventive Services Task Force (USPSTF) has recommended against thyroid cancer screening in asymptomatic individuals. The current USPSTF statement is an update of a 1996 USPSTF recommendation statement. The recommendation was based on task force review of evidence on...
FDA Grants Accelerated Approval to Avelumab for Urothelial Carcinoma
Today, the U.S. Food and Drug Administration (FDA) granted accelerated approval to avelumab (Bavencio) for patients with locally advanced or metastatic urothelial carcinoma whose disease progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant...
Intermittent Vismodegib Regimens in Basal Cell Cancers
In a phase II trial reported in The Lancet Oncology, Brigitte Dréno, MD, of Nantes University, Nantes, France, and colleagues found that two long-term intermittent vismodegib (Erivedge) dosing regimens provided a similar reduction in the number of clinically significant basal cell carcinomas among...
Sentinel Lymph Node Biopsy vs Lymphadenectomy in Endometrial Cancer Staging
In the FIRES prospective cohort study reported in The Lancet Oncology, Emma C. Rossi, MD, of the University of North Carolina, Chapel Hill, and colleagues found that sentinel lymph node mapping was highly accurate in detecting metastases compared with complete lymphadenectomy in women with...
Never Smokers Account for Increased Proportion of NSCLC Cases
In a retrospective study in three U.S. institutions reported in the Journal of the National Cancer Institute, Pelosof et al found that never smokers accounted for an increasing proportion of cases of non–small cell lung cancer (NSCLC) during the period from 1990 to 2013. Joan Schiller, MD, of the...
Gefitinib or Erlotinib vs Chemotherapy in Advanced NSCLC
In an individual patient data meta-analysis reported in the Journal of the National Cancer Institute, Lee et al found no difference in overall survival for first-line treatment with the first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors gefitinib (Iressa) or...
Saving My Hair Changed My Perception of Having Cancer
Getting a callback after a routine screening mammogram in 2013 did not set off any alarm bells. Having dense breasts has almost guaranteed receiving the dreaded callback ever since I started getting annual screenings. But when I got a second callback after additional images of a suspicious lesion...
Luis A. Diaz, MD, Named Head of Solid Tumor Oncology at MSK
Luis A. Diaz, MD, has been named Head of the Division of Solid Tumor Oncology in the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK). Dr. Diaz most recently served as Associate Professor of Oncology at the Johns Hopkins University School of Medicine. Dr. Diaz formally...
A New Book Deals With an Age-Old Crisis: Cancer Patients and Mortality
The field of psycho-oncology began to take hold in the mid-1970s, when the “C” word was beginning to lose its long-held stigmatization, and patients with cancer could finally begin to openly reveal their diagnosis and express their feelings about their life-threatening disease. Despite that social ...
ELCC 2017: Prospective Study Shows Concordance of EGFR Mutation Detection Between ctDNA and Tumor Samples
Detection of EGFR mutations in circulating tumor (ct) DNA from plasma samples can be accomplished using the cobas platform, according to findings presented by Kumar et al at the 2017 European Lung Cancer Conference (ELCC) (Abstract 95PD). Assays of ctDNA offer a noninvasive method of finding EGFR...
Lenalidomide as Maintenance Therapy in Multiple Myeloma After Autologous Stem Cell Transplantation
On February 22, lenalidomide (Revlimid) was approved as maintenance therapy for patients with multiple myeloma following autologous hematopoietic stem cell transplantation.1,2 The drug was previously approved to treat multiple myeloma (in combination with dexamethasone), anemia caused by...
Ahmad Samer Al-Homsi, MD, MBA, to Lead New Bone Marrow Transplantation Initiative at NYU
Hematologist-oncologist Ahmad Samer Al-Homsi, MD, MBA, will lead a new bone marrow transplantation program at New York University (NYU) Langone’s Perlmutter Cancer Center for treating blood-borne cancers and potentially utilize transplantation as an adjunct to immunotherapy for solid tumors. He...
ELCC 2017: Specific Immune Cell Profiles Potentially Identify Patients With Lung Cancer Responsive to Anti–PD-1 Immunotherapy
An investigation of immune cell subtypes in the tumor microenvironment of patients with lung adenocarcinoma and squamous cell carcinoma (SCC) identified an immune subgroup that associates with prolonged patient survival and may be prognostic of response to nivolumab, according to findings presented ...
Avelumab in Merkel Cell Carcinoma
On March 23, 2017, avelumab (Bavencio) was granted accelerated approval for treatment of patients aged ≥ 12 years with metastatic Merkel cell carcinoma. Avelumab is the first U.S. Food and Drug Administration–approved product to treat this disease.1,2 Supporting Efficacy Data Approval was based on ...
Expanding Role Seen for Minimal Residual Disease in Managing Multiple Myeloma
Minimal residual disease is a promising biomarker for guiding the management of multiple myeloma that is becoming increasingly important with the advent of more efficacious therapies, according to emerging data and expert opinion. “The story of minimal residual disease in multiple myeloma is like...
Blinatumomab ‘Takes a BiTE’ Out of Acute Lymphoblastic Leukemia
An investigational immunotherapy is improving outcomes in difficult-to-treat acute lymphoblastic leukemia (ALL) and showing promise in other cancers, as well. Blinatumomab (Blincyto), the first U.S. Food and Drug Administration (FDA)-approved bispecific T-cell engager (BiTE), has demonstrated...
ELCC 2017: Ensartinib Demonstrates CNS Activity in ALK-Positive NSCLC
Ensartinib demonstrated intracranial responses in patients with anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancer (NSCLC) and central nervous system (CNS) metastases, according to findings presented by Reckamp et al at the 2017 European Lung Cancer Conference (ELCC)...
Immune System Is Shaping the Future of Multiple Myeloma Treatment
From immunomodulatory agents and proteasome inhibitors to steroids, alkylators, and antibodies, recent years have witnessed an explosion of drug approvals for multiple myeloma. The challenge now, said Amrita Krishnan, MD, FACP, is figuring out how to incorporate them all, particularly in the...
Social Media: A Knowledge-Sharing Tool in Oncology
Social media is a uniquely positioned platform that can spread specific knowledge to a larger audience. Unlike traditional media, it allows anyone to join the conversation, and according to the Pew Research Center, it is here to stay, with 79% of online American adults using Facebook and 24% using...
QOPI® Certification Program Certifies First Practice in Brazil
On April 5, ASCO announced that Instituto de Oncologia do Vale (IOV) was the first practice in Brazil to receive Quality Oncology Practice Initiative (QOPI®) certification through the QOPI Certification Program, LLC (QCP). IOV is the second international practice to achieve this milestone in...
ELCC 2017: Development and Validation of Lung Toxicity Prediction Models Aids Effective Use of Radiotherapy in NSCLC
Validation using patient data of an outcome prediction model for the development of dyspnea subsequent to radiotherapy revealed that the prognostic factors in the model did not adequately predict for delta toxicity endpoints, according to results reported by Defraene et al at the 2017 European Lung ...
Donor Spotlight: Conquering Cancer With Kelly Cares Foundation
Kelly Cares Foundation recently became one of the newest supporters of the Conquer Cancer Foundation of ASCO Young Investigator Awards, the flagship program begun in 1984 to support early-career cancer researchers. The mission of Kelly Cares Foundation is to inspire hope by investing resources to...
Neoadjuvant Immunotherapy in High-Risk Melanoma: A New Approach
Melanoma is an immunogenic tumor, as it expresses various melanoma-specific antigens. However, it is both biologically and clinically heterogeneous. Biologically, it expresses different melanoma antigens and has diverse genetic profiles among different patients. Clinically, it varies in the amount ...
Prognostic and Predictive Effects of TP53 With KRAS or EGFR Mutation Status in NSCLC
In a pooled analysis of four trials of platinum adjuvant therapy vs observation in resected early-stage non–small cell lung cancer (NSCLC), Shepherd et al found no prognostic effect of KRAS or EGFR with TP53 comutation but a potential negative predictive effect for adjuvant therapy with TP53...
Final, 10-Year Follow-up of Phase III Trial on Adding Gemcitabine to Adjuvant Therapy in Breast Cancer
The final, 10-year follow-up of the ‘all comers’ tAnGo trial, reported by Earl et al in The Lancet Oncology, continued to show no overall benefit of adding gemcitabine to adjuvant therapy in women with early-stage breast cancer. The trial, initiated in 2001, included patients...
Karmanos Cancer Institute Now Offers Image-Fusion Technology to Detect Prostate Cancer
The Barbara Ann Karmanos Cancer Institute is using a sophisticated new way to diagnose and treat prostate cancer more effectively. Urology specialists at Karmanos have begun using the UroNav Fusion Biopsy System, which fuses three-dimensional MRI (magnetic resonance imaging) images of the prostate...
Selected Abstracts From the 2016 ASH Annual Meeting
Here are several abstracts selected from the proceedings of this year’s American Society of Hematology (ASH) Annual Meeting & Exposition, highlighting newer therapeutics in various types of high-grade, aggressive non-Hodgkin lymphomas (NHLs), including peripheral T-cell lymphomas, central...
Expert Point of View: Kelly M. McMasters, MD, PhD
“More and more, we are finding that traditional anatomic TNM staging has significant limitations in predicting prognosis, especially in such cases where response to therapy is an important consideration,” commented session moderator Kelly M. McMasters, MD, PhD, a surgical oncologist at the...
Neo-Bioscore Improves Staging of Breast Cancer Treated With Neoadjuvant Chemotherapy
A new score that incorporates tumor biology and response outperforms conventional histopathologic criteria for the staging of breast cancer treated with neoadjuvant chemotherapy, finds a retrospective validation cohort study.1 Investigators led by John R. Bergquist, MD, MS, MA, a general surgery...
Expert Point of View: Daniel G. Coit, MD
“While these results are clearly superior to historical controls, the study prompts a number of questions,” session moderator, Daniel G. Coit, MD, a surgical oncologist at Memorial Sloan Kettering Cancer Center in New York, commented in an interview. “Nearly half of the patients received systemic ...
Hyperthermic Intraperitoneal Chemoperfusion May Be Efficacious for Peritoneal Metastases
Hyperthermic intraperitoneal chemoperfusion is efficacious when used as part of multimodality therapy for low-volume peritoneal metastases of gastric cancer, suggests a prospective single-arm phase II trial.1 Among the 19 patients enrolled, all of whom had stage IV disease with either...
